Expansion of Pipeline Including Four Promising Candidates Such as Venadaparib
Idions, a new drug development subsidiary of Ildong Pharmaceutical Group, plans to expand its oncology drug R&D (research and development) pipeline and accelerate commercialization efforts including clinical development.
According to industry sources on the 10th, Idions will participate in major oncology academic conferences, including the upcoming American Association for Cancer Research (AACR) next month, to unveil new drug candidates.
Idions is a specialized oncology new drug development company within the Ildong Pharmaceutical Group. It focuses its capabilities on innovative cancer drug development through collaboration with R&D affiliates such as Ildong Pharmaceutical, IRBM, and AIMS Bioscience within the group, as well as partnerships with domestic and international academia and medical institutions.
In May last year, Idions signed a strategic alliance with Dong-A ST involving approximately 25 billion KRW equity investment and joint development of oncology new drugs, recognizing its R&D capabilities and the value of its new drug pipeline in the oncology field.
Currently, Idions holds multiple oncology new drug candidates, including Venadaparib, a PARP (Poly ADP-ribose polymerase) inhibitor, and is accelerating clinical development.
Venadaparib is an oral targeted therapeutic oncology drug candidate that selectively induces cancer cell death by inhibiting PARP, an enzyme involved in repairing cellular DNA damage. In 2022, it was designated by the U.S. FDA as an orphan drug for gastric cancer treatment. Venadaparib selectively exhibits toxicity against cancer cells, significantly improving hematologic safety compared to first-generation PARP inhibitors. It is a next-generation PARP inhibitor with potential for expanded indications and usage through combination therapies with various anticancer agents.
Through various studies and clinical data from over 200 patients, Idions has confirmed Venadaparib’s excellent therapeutic effects not only for gastric cancer but also for breast cancer, ovarian cancer, and pancreatic cancer. Last year, Idions completed a Phase 2a clinical trial of Venadaparib for breast cancer and is currently conducting a Phase 2a combination therapy clinical trial for gastric cancer in Korea and the United States.
In addition to Venadaparib, Idions recently secured promising candidates including the cancer stem cell-targeting anticancer agent 'ID12023,' the KRAS mutation-targeting anticancer agent for non-small cell lung cancer, pancreatic cancer, and colorectal cancer 'ID12241,' the refractory prostate cancer treatment 'ID11916,' and the antibody-drug conjugate (ADC) 'ID12401' utilizing a novel payload, and has commenced related research.
The company plans to participate in the American Association for Cancer Research (AACR) conference starting on the 25th of next month, where it will present four latest research results related to newly added oncology drug pipeline candidates, including an oral presentation on the 'ID12023' study.
Won-sik Lee, CEO of Idions, stated, "We have secured multiple promising oncology new drug candidates including Venadaparib and are conducting clinical research and development projects. Having confirmed the potential and differentiation of these candidates through various preclinical and clinical studies, we plan to accelerate commercialization efforts."
Idions intends to continuously promote its global competitiveness in the oncology field through overseas academic events such as AACR and business conferences, while simultaneously pursuing business partner discovery through open innovation and licensing-out (technology export).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
